Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 5,329 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 5,329 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $67,198.69. Following the transaction, the insider directly owned 130,887 shares of the company’s stock, valued at $1,650,485.07. This trade represents a 3.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Trading Down 2.7%

Shares of NASDAQ:BBNX opened at $12.45 on Thursday. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The company has a 50-day moving average price of $10.83 and a 200 day moving average price of $17.31. The company has a market cap of $554.59 million, a price-to-earnings ratio of -8.24 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The firm had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. As a group, equities analysts forecast that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC lifted its stake in shares of Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after buying an additional 37,476 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Beta Bionics by 2.6% during the third quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after buying an additional 110,000 shares during the period. Soleus Capital Management L.P. lifted its stake in shares of Beta Bionics by 12.5% during the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the period. Vanguard Group Inc. lifted its stake in shares of Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after buying an additional 1,509,217 shares during the period. Finally, Eversept Partners LP lifted its stake in shares of Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after buying an additional 736,576 shares during the period.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics said it is now publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support investor confidence in the company’s commercial progress and transparency. Article Title
• Neutral Sentiment: Several top executives disclosed stock sales on June 2, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger. Each sale was relatively small and was stated to be for tax withholding related to vesting equity awards, which makes the transactions less concerning than open-market selling, but the volume may still weigh on sentiment.
• Negative Sentiment: Multiple law firms, including Robbins LLP and Johnson Fistel, announced investigations into Beta Bionics and its officers/directors over possible securities-law violations and investor losses. These headlines suggest litigation risk and can spark concerns about disclosure practices and governance. Article Title
• Negative Sentiment: A shareholder alert said Robbins LLP is investigating whether Beta Bionics executives and directors violated securities laws and breached fiduciary duties, adding to the legal overhang. Article Title
• Negative Sentiment: Johnson Fistel also said it is investigating whether investors suffered losses after Beta Bionics reported slower new patient start growth, highlighting concerns that growth momentum may be decelerating. Article Title

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BBNX shares. Leerink Partners reduced their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Bank of America reduced their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Robert W. Baird dropped their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group dropped their price objective on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.